149 related articles for article (PubMed ID: 21289145)
21. Performance evaluation of the COBAS/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low viral load: a comparative study.
Paba P; Fabeni L; Ciccozzi M; Perno CF; Ciotti M
J Virol Methods; 2011 May; 173(2):399-402. PubMed ID: 21419171
[TBL] [Abstract][Full Text] [Related]
22. Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
Boyd SD; Maldarelli F; Sereti I; Ouedraogo GL; Rehm CA; Boltz V; Shoemaker D; Pau AK
Antivir Ther; 2011; 16(2):257-61. PubMed ID: 21447876
[TBL] [Abstract][Full Text] [Related]
23. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
[TBL] [Abstract][Full Text] [Related]
24. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
[TBL] [Abstract][Full Text] [Related]
25. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B
J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211
[TBL] [Abstract][Full Text] [Related]
26. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir.
Bercoff DP; Triqueneaux P; Lambert C; Oumar AA; Ternes AM; Dao S; Goubau P; Schmit JC; Ruelle J
Retrovirology; 2010 Nov; 7():98. PubMed ID: 21114823
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections.
Church D; Gregson D; Lloyd T; Klein M; Beckthold B; Laupland K; Gill MJ
J Clin Microbiol; 2011 Jan; 49(1):118-24. PubMed ID: 21084515
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the Abbott m2000 HIV-1 Real-Time and Roche AMPLICOR Monitor v1.5 HIV-1 assays on plasma specimens from Rakai, Uganda.
Ssebugenyi I; Kizza A; Mpoza B; Aluma G; Boaz I; Newell K; Laeyendecker O; Shott JP; Serwadda D; Reynolds SJ
Int J STD AIDS; 2011 Jul; 22(7):373-5. PubMed ID: 21729954
[TBL] [Abstract][Full Text] [Related]
29. In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
Charpentier C; Bertine M; Visseaux B; Leleu J; Larrouy L; Peytavin G; Mourez T; Collin G; Brun-Vézinet F; Plantier JC; Descamps D
AIDS; 2013 Nov; 27(18):2959-61. PubMed ID: 23942060
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays.
Scott LE; Noble LD; Moloi J; Erasmus L; Venter WD; Stevens W
J Clin Microbiol; 2009 Jul; 47(7):2209-17. PubMed ID: 19420172
[TBL] [Abstract][Full Text] [Related]
31. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
32. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Orta-Resendiz A; Rodriguez-Diaz RA; Angulo-Medina LA; Hernandez-Flores M; Soto-Ramirez LE
AIDS Res Ther; 2020 Feb; 17(1):6. PubMed ID: 32041622
[TBL] [Abstract][Full Text] [Related]
34. Analysis of transmitted resistance to raltegravir and selective pressure among HIV-1-infected patients on a failing HAART in Sao Paulo, Brazil.
Mantovani NP; Azevedo RG; Rabelato JT; Sanabani S; Diaz RS; Komninakis SV
J Clin Microbiol; 2012 Jun; 50(6):2122-5. PubMed ID: 22403424
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the RealTime HIV-1, Xpert HIV-1, and Aptima HIV-1 Quant Dx Assays in Comparison to the NucliSens EasyQ HIV-1 v2.0 Assay for Quantification of HIV-1 Viral Load.
Mor O; Gozlan Y; Wax M; Mileguir F; Rakovsky A; Noy B; Mendelson E; Levy I
J Clin Microbiol; 2015 Nov; 53(11):3458-65. PubMed ID: 26292298
[TBL] [Abstract][Full Text] [Related]
36. Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent for nucleic acid testing assays.
Amendola A; Marsella P; Bloisi M; Forbici F; Angeletti C; Capobianchi MR
J Clin Microbiol; 2014 Jun; 52(6):2019-26. PubMed ID: 24671791
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.
Varghese V; Liu TF; Rhee SY; Libiran P; Trevino C; Fessel WJ; Shafer RW
AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1323-6. PubMed ID: 20961278
[TBL] [Abstract][Full Text] [Related]
39. Multicenter Evaluation of Two Next-Generation HIV-1 Quantitation Assays, Aptima Quant Dx and Cobas 6800, in Comparison to the RealTi
Wiesmann F; Ehret R; Naeth G; Däumer M; Fuhrmann J; Kaiser R; Noah C; Obermeier M; Schalasta G; Tiemann C; Wolf E; Knechten H; Braun P
J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30068537
[TBL] [Abstract][Full Text] [Related]
40. The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro.
Saladini F; Giannini A; Boccuto A; Tiezzi D; Vicenti I; Zazzi M
AIDS; 2017 Oct; 31(16):2307-2309. PubMed ID: 28832412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
